These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35790537)

  • 1. Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.
    Long Y; Lv X; Song X; Shao F; Ji H; Zhang Y; Qiao P; Liu Q; Xia X; Lei P; Gai Y; Lan X
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4156-4170. PubMed ID: 35790537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET Imaging of VLA-4 in a New BRAF
    Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
    Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
    Beaino W; Nedrow JR; Anderson CJ
    Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
    Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
    J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
    Beaino W; Anderson CJ
    J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evaluation of
    Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
    Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
    Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
    J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Al
    Gai Y; Yuan L; Sun L; Li H; Li M; Fang H; Altine B; Liu Q; Zhang Y; Zeng D; Lan X
    J Biol Inorg Chem; 2020 Feb; 25(1):99-108. PubMed ID: 31745667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
    Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
    PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of New Bifunctional Chelators with Phosphonic Acid Arms for Gallium-68 Based PET Imaging in Melanoma.
    Gai Y; Sun L; Lan X; Zeng D; Xiang G; Ma X
    Bioconjug Chem; 2018 Oct; 29(10):3483-3494. PubMed ID: 30205001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Metal-Free DOTA-Conjugated
    Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
    Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
    Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
    J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
    Haddad J; Latoche JD; Nigam S; Bellavia MC; Day KE; Zhu Q; Edwards WB; Anderson CJ; Tavakoli S
    J Nucl Med; 2021 Feb; 62(2):280-286. PubMed ID: 32680928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.
    Mattila JT; Beaino W; Maiello P; Coleman MT; White AG; Scanga CA; Flynn JL; Anderson CJ
    J Immunol; 2017 Jul; 199(2):806-815. PubMed ID: 28592427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo PET Tracking of
    Man F; Lim L; Volpe A; Gabizon A; Shmeeda H; Draper B; Parente-Pereira AC; Maher J; Blower PJ; Fruhwirth GO; T M de Rosales R
    Mol Ther; 2019 Jan; 27(1):219-229. PubMed ID: 30429045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
    Jiang M; Ferdani R; Shokeen M; Anderson CJ
    Nucl Med Biol; 2013 Feb; 40(2):245-51. PubMed ID: 23265977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice.
    Perkins LA; Nyiranshuti L; Little-Ihrig L; Latoche JD; Day KE; Zhu Q; Tavakoli S; Sundd P; Novelli EM; Anderson CJ
    Blood Adv; 2020 Sep; 4(17):4102-4112. PubMed ID: 32882004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of PET Imaging for Prognostic Integrin α
    Huang CW; Hsieh WC; Hsu ST; Lin YW; Chung YH; Chang WC; Chiu H; Lin YH; Wu CP; Yen TC; Huang FT
    Theranostics; 2017; 7(16):4013-4028. PubMed ID: 29109795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Preclinical Evaluation of a
    Li H; Yuan L; Long Y; Fang H; Li M; Liu Q; Xia X; Qin C; Zhang Y; Lan X; Gai Y
    Mol Pharm; 2020 Aug; 17(8):3000-3008. PubMed ID: 32544337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of
    Maresca KP; Chen J; Mathur D; Giddabasappa A; Root A; Narula J; King L; Schaer D; Golas J; Kobylarz K; Rosfjord E; Keliher E; Chen L; Ram S; Pickering EH; Hardwick JS; Rejto PA; Hussein A; Ilovich O; Staton K; Wilson I; McCarthy TJ
    Mol Imaging Biol; 2021 Dec; 23(6):941-951. PubMed ID: 34143379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.